Gavilimomab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A murine IgM monoclonal antibody (MoAb) developed for the potential treatment of graft versus host disease (GvHD). MoAb ABX-CBL recognizes human CD147 antigen, weakly expressed on human leukocytes and up-regulated on activated lymphocytes. This MoAb is capable of neutralizing inflammatory reactions via a complement-dependent cytotoxic mechanism. However, MoAb ABX-CBL does not offer an improvement over antithymocyte globulin in the treatment of acute steroid resistant GVHD.

**Synonyms:** - GAVILIMOMAB - Monoclonal Antibody ABX-CBL - anti-CD147 Monoclonal Antibody ABX-CBL